Full Breakdown
New York's Superbug Crisis: The Rise of Antibiotic Resistance
3/18/2026, 2:40:59 PM
The Emergence of Superbugs in New York
New York City is currently facing a significant public health challenge with the rise of "superbugs," particularly the fungus Candida auris. This pathogen, which was first detected in the state in 2016, has shown a steady increase in clinical cases, with 623 reported last year, alongside 849 surveillance cases. The NYC/New Jersey metro area accounts for nearly 20% of the United States' Candida auris cases, attributed to high-volume travel and trade with South Asia. Candida auris is particularly concerning as it survives on surfaces even after cleaning and often evades standard antifungal treatments, leading to severe bloodstream infections.
The Role of Antibiotic Overuse
Medical experts highlight that the overuse of antibiotics is a critical factor contributing to the rise of antibiotic-resistant bacteria, often referred to as "nightmare bacteria." Dr. Aaron Glatt, a professor and chair of the Department of Medicine at Mount Sinai South Nassau, emphasizes that antibiotics should only be used for bacterial infections, such as strep throat and pneumonia, and not for viral illnesses like colds or COVID-19. The World Health Organization has reported that 1 in 6 bacterial infections are resistant to common antibiotic treatments, with resistance rates increasing by 5% to 15% annually from 2018 to 2023.
Impact of the COVID-19 Pandemic
The COVID-19 pandemic exacerbated the issue of antibiotic resistance, as many patients with mild to moderate cases received antibiotics unnecessarily. Dr. Glatt notes that this trend is partly due to patients requesting antibiotics when they are not needed. While Candida auris primarily spreads within healthcare facilities, it poses a heightened risk to immunocompromised patients, particularly those in nursing homes who have received multiple antibiotics.
Legislative Efforts to Combat Resistance
In response to the growing threat of antibiotic resistance, federal bipartisan legislation known as the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act has been proposed. This act aims to incentivize pharmaceutical companies to develop new antibiotics through a subscription model, where payments are based on the value and innovation of the drugs rather than the volume sold. This approach is intended to stabilize the market and encourage ongoing research and development in the field of antibiotics.
Criticism & Opposition
Despite the efforts to combat antibiotic resistance, there are concerns regarding the effectiveness of current strategies. Critics argue that the reliance on new legislative measures may not address the root causes of antibiotic overuse and resistance. The challenge remains to change prescribing practices and patient expectations regarding antibiotic treatments.
Verbatim Quotes
- “When somebody has a viral illness, they have a respiratory cold, [an] antibiotic [will] have zero benefit to them, but will have more potential toxicity, both in terms of side effects and reactions, but also in the development of resistance,” — Dr. Aaron Glatt, Mount Sinai South Nassau
- “It is not something that is of great concern to the typical person on the street,” — Dr. Aaron Glatt, Mount Sinai South Nassau
- “This Netflix model says the government will pay the pharmaceutical [companies] a flat fee for the access to these antibiotics, no matter how much is used or not,” — Dr. Aaron Glatt, Mount Sinai South Nassau
The situation in New York underscores the urgent need for public awareness and responsible antibiotic use to mitigate the growing threat of superbugs and antibiotic resistance.
